• Calidi Biotherapeutics presented preclinical cancer therapy results at the ESMO Congress in Madrid on October 24, 2026.
• Lead candidate CLD-401 eliminated tumors in most treated mice with breast cancer; a bladder cancer model showed activity with intravenous or intratumoral delivery.
• CLD-501 and CLD-502 supported localized production of tumor-targeted T-cell engagers, which demonstrated antigen-dependent cancer-cell killing in preclinical studies.
• The RedTail platform enabled T-cell engager production within tumors without administering the engager protein systemically, supporting its localized treatment approach.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270800PRIMZONEFULLFEED9853644) on October 27, 2026, and is solely responsible for the information contained therein.